€9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.

Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival.

Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) presented a preliminary analysis of the data from 21 glioblastoma patients who received 65 SonoCloud® treatments. Overall Survival was increased from 8.5 to 12.9 months in patients who had SonoCloud®-induced BBB opening.

May 2018 – CarThera will participate to BIO 2018 in Boston

CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at contact@carthera.eu and come to Booth 527 at the France Pavilion.

The clinical data from the trial involving 21 patients with recurrent glioblastoma, who have all been treated with SonoCloud® low-intensity pulsed ultrasound in a total of 65 sessions, have been shared with more than 30,000 oncology professionals from around the world.

CarThera secures €5.7 million in funding for its DOME project

October 12, 2016 – CarThera has received a grant of €5.7 million ($6.4m) for its DOME project. The funding was awarded under the call for proposals ‘Structuring R&D Projects for Competitiveness’ from France’s ‘Investments for the Future Program’, led by the General Investment Commission and run by Bpifrance.

The grant will finance our SonoCloud Phase 2b/3 study in glioblastoma that will involve around 200 patients at centers in Europe and the United States. It will also fund a number of exploratory studies, including one on Alzheimer’s disease, building on the findings from the Phase 1/2a study that paved the way for a broader array of clinical indications.

Scientific paper published on June 15th 2016 in Science Translational Medicine supports concept of intracranial ultrasound implant developed by CarThera

Research teams from AP-HP hospitals, UPMC University, INSERM laboratories and the ICM incubator performed this breakthrough on brain tumors, paving the way for broader applications in neurological disorders

The Biovision 2016 Investor Conference selection committee special award went to CarThera!

The Investor Conference of Biovision is a unique opportunity for selected startups (28 over 120 candidates) to pitch in front of a jury of 15 of the major European VC.

Biovision, The World Life Sciences Forum, brings together international decision makers from the academic, private, policy-making and civil society sectors. It took place 13–14 April 2016 in Lyon, France.

Brain Tumors: ultrasound opens new perspectives

“Destroying complex shape tumors using MR guided ultrasound probes, opening the Blood-Brain Barrier with an ultrasound implant: ultrasound could be a major game changer for the treatment of brain tumors in the future” according to an article published in June 22nd 2015, in the French journal “Le Quotidien Du Medecin” based on an interview of Professor Alexandre Carpentier.

CarThera closes its round A to open the cerebral barrier

In the issue 675 of BIOTECH FINANCES news CarThera announces the closing of a 2.1M€ round A with a pool of private investors.

With this financing round the company will serenely move forward its clinical developments, and more specifically its phase 1 trial for the SonoCloud® device.

Brain barrier opened for first time to treat cancer

The title used by the magazine newscientist.com to summarize the conference talk given by Dr. Michael Canney (CTO CarThera) on CarThera’s clinical work with the SonoCloud®. The work was presented at the Focused Ultrasound Foundation (FUS) Symposium in Bethesda, Maryland in October 2014.

“For the first time, doctors have opened and closed the brain’s protector – the blood-brain barrier – on demand. The breakthrough will allow drugs to reach diseased areas of the brain that are otherwise out of bounds. Ultimately, it could make it easier to treat conditions such as Alzheimer’s and brain cancer … ” click here to read the full article on newscientist.com.

Pr. Carpentier honored by Mr. Hirsch for his 2014 USA patent delivery

Annual day of the Technology Transfert Department of APHP (Assistance Publique – Hopitaux de Paris)

During the Apinnov plenary session, Mr. Martin HIRSCH CEO of AP-HP congratuled Pr. Alexandre Carpentier as well as 9 other authors from APHP for their 2014 delivered patents. Alexandre Carpentier was awardedfor his 2014 USA patent delivery on interstitial probe treatment.

APINNOV

JUNE 17, 2014 – Apinnov 2014

Annual day of the Technology Transfert Department of APHP (Assistance Publique – Hopitaux de Paris)

CarThera has been selected by a jury of international Venture Capitalists to present during the Biovision Investor Conference. The presentation of the company is planned to take place on Friday June 5 at 8:30.

The most promising company will be announced and receive an award during the Biovision Closing Ceremony on June 6 between 14:00 and 15:30.

A new management team

Frederic Sottilini MS MBA, a medical device professional, former Marketing Director at EDAP, General Manager at Accuray Europe and Business Manager at Philips, joined CarThera as the new CEO.

Dominique Costantini MD PhD, a pharmaceutical professional, founder of BioAlliance Pharma, joined CarThera as the new Chairman.

CarThera Clinical Advisory Board Meeting

The first Clinical Advisory Board of CarThera was held in New York City on Febuary 13, 2014. It was a good opportunity to receive the various points-of-vue from different KOL experts (neuro-oncologists, neurosurgeons). All bring their support to CarThera’s developments, and are ready to participate in the future multi-centric pivotal study of SonoCloud, for which a protocole design has been defined.

News CarThera

13.12.2018

CarThera closes €9M ($10.3M) Series B funding round

€9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.

CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at contact@carthera.eu and come to Booth 527 at the France Pavilion.